10-Q/A: Dalrada Financial Corp Faces Deepening Losses and Going Concern Doubts Amidst Plummeting Revenues

Dalrada Financial Corporation reported a significant decline in revenues and widening net losses for the quarter and nine months ended March 31, 2024, raising substantial doubt about its ability to continue as a going concern.

Summary

• Dalrada Financial Corporation filed an amended Quarterly Report on Form 10-Q/A for the period ended March 31, 2024, primarily to correct revenue and accounts receivable figures.
• The company reported a total revenue of $3,428,733 for the three months ended March 31, 2024, a 63.8% decrease from $9,474,693 in the same period last year.
• For the nine months ended March 31, 2024, total revenues were $14,524,575, down 23.5% from $18,985,580 in the prior year period.
• Gross profit turned into a loss of $(1,653,082) for the three months ended March 31, 2024, compared to a profit of $2,862,013 in the prior year.
• Net loss for the three months ended March 31, 2024, increased to $(9,272,142) from $(4,045,798) in the comparative period.
• For the nine months ended March 31, 2024, the net loss was $(19,550,458), significantly higher than $(11,698,139) for the nine months ended March 31, 2023.
• The company's accumulated deficit grew to $(161,198,804) as of March 31, 2024.
• Net cash used in operating activities for the nine months ended March 31, 2024, was $(5,660,542), an improvement from $(10,074,709) in the prior year.
• Working capital improved to a positive $3,009,666 as of March 31, 2024, from a deficit of $(202,420) as of June 30, 2023.
• The company explicitly states that its net losses, accumulated deficit, and negative operating cash flow raise substantial doubt about its ability to continue as a going concern.
• Stock-based compensation expense increased to $3,205,859 for the nine months ended March 31, 2024, from $2,184,692 in the prior year period.
• Proceeds from related party notes payable significantly decreased to $2,913,980 for the nine months ended March 31, 2024, from $11,845,764 in the prior year period.
• The company reported material weaknesses in its internal control over financial reporting, specifically lacking a comprehensive and formalized financial reporting policies and procedures manual.
• Several legal proceedings are ongoing, including a lawsuit regarding misappropriation of funds in a joint venture and preliminary injunctions related to non-compete clauses for employees of a subsidiary.
• The company's OTC Markets status changed to the Expert Market on January 15, 2025.

Sentiment

Score: 2

Explanation: The company faces severe financial distress, marked by substantial net losses, a growing accumulated deficit, and explicit going concern doubt. Revenue has plummeted across most segments, and while working capital improved, the company remains heavily reliant on related party financing. Persistent material weaknesses in internal controls and recent high-profile resignations of board members and the auditor further compound the negative outlook, indicating significant operational and governance challenges.

Positives

• Working capital improved significantly from a deficit of $(202,420) as of June 30, 2023, to a positive $3,009,666 as of March 31, 2024.
• Net cash used in operating activities decreased by approximately 43.8% to $(5,660,542) for the nine months ended March 31, 2024, compared to $(10,074,709) in the prior year, indicating a reduced cash burn from operations.
• Dalrada Career Institute (DCI) commenced its first RN nursing class in February 2024, with plans to double class size in 2025, signaling growth in its educational segment.
• The company acquired 100% of IV Services, LLC, a pharmacy business, on May 7, 2024, expanding its Genefic Infusion RX segment.
• Dalrada Home Corporation was established in February 2024 to focus on residential sustainability solutions, including home heat pumps.
• An Exclusive Master Distribution Agreement was signed with Applied Technologies of NY, Inc. on August 12, 2024, setting sales goals for commercial and residential heat pumps.
• The company engaged CM3 Advisory as its new auditor on October 18, 2024, and nominated Roger Campos as a new Board member on October 23, 2024.

Negatives

• Total revenues for the three months ended March 31, 2024, decreased by 63.8% to $3,428,733, and for the nine months, they decreased by 23.5% to $14,524,575.
• Gross profit for the three months ended March 31, 2024, became a loss of $(1,653,082), a significant deterioration from a profit of $2,862,013 in the prior year period.
• Net loss for the three months ended March 31, 2024, increased by 129.2% to $(9,272,142), and for the nine months, it increased by 67.1% to $(19,550,458).
• The accumulated deficit expanded to $(161,198,804) as of March 31, 2024, indicating a substantial history of losses.
• Cash and cash equivalents decreased to $533,595 as of March 31, 2024, from $812,806 as of June 30, 2023.
• Proceeds from related party notes payable, a key source of financing, decreased by 75.4% for the nine months ended March 31, 2024, compared to the prior year.
• Pala Diagnostics, a joint venture, ceased operations as of June 30, 2023.
• EIDL loans are technically in default due to a change in ownership without the Small Business Administration's prior written consent.
• Two board members, Vince Monteparte and Heather McMahon, resigned in October 2024.
• Assurance Dimensions resigned as the company's auditor on October 12, 2024.
• The company's OTC Markets status changed to the Expert Market on January 15, 2025, which can limit trading visibility and liquidity.

Risks

• The company's significant net losses of $19,550,458, accumulated deficit of $161,198,804, and net cash used in operations of $5,660,542 for the nine months ended March 31, 2024, raise substantial doubt about its ability to continue as a going concern for the next twelve months.
• The company is dependent on continued financial support from related parties and its ability to obtain necessary debt or equity financing to fund operations and execute business plans, with no assurance of successful outcomes.
• The company incurs increased legal, accounting, and compliance costs as a publicly traded company, which may make it difficult to attract and retain qualified board members or executive officers.
• Material weaknesses in internal control over financial reporting persist, including the lack of a comprehensive financial reporting policies and procedures manual and inadequate schedules for consolidated entities, increasing the risk of material misstatements.
• Ongoing legal proceedings, including a lawsuit for misappropriation of funds in a joint venture and preliminary injunctions related to non-compete clauses, pose financial and operational risks.
• Certain EIDL loans are technically in default due to changes in ownership without prior consent from the Small Business Administration.
• The fair value of contingent consideration obligations is subject to volatility based on actual results compared to management's assumptions, potentially causing material impacts on operating results.

Future Outlook

Management plans to support operations by raising additional capital and accelerating sales and marketing efforts for high-margin products, including Likido heating & cooling units, precision parts, Dalrada Energy Services, DepTec's deposition systems, and COVID-19 testing. The Dalrada Career Institute intends to double its RN nursing class size in 2025.

Management Comments

• "Our net loss and limited working capital raise substantial doubt about our ability to continue as a going concern."
• "We will be required to raise substantial capital to fund our capital expenditures, working capital, and other cash requirements."
• "We will continue to rely on related parties and seek other financing to complete our business plans."
• "The successful outcome of future financing activities cannot be determined at this time and there are no assurances that, if achieved, we will have sufficient funds to execute our intended business plan or generate positive operational results."
• "We are incurring increased costs as a result of being a publicly traded company."
• "We undertake no obligation to update publicly any forward-looking statements for any reason, even if new information becomes available or other events occur in the future."

Industry Context

Dalrada Financial Corporation operates across diverse sectors including healthcare, climate technology, precision manufacturing, and general technology. The significant decline in Genefic's revenue is primarily attributed to a decrease in high-volume COVID-19 related sales, reflecting a broader trend of reduced demand for such services. The company's continued focus on climate technology, particularly heat pumps, aligns with global trends towards clean energy and sustainability, though its current financial performance in this segment indicates challenges in market penetration or project execution. The overall revenue decline across most segments suggests either intense competitive pressures, a failure to secure new large contracts, or internal operational inefficiencies within its varied business lines.

Comparison to Industry Standards

• The company's substantial net losses and accumulated deficit, coupled with explicit going concern doubt, are significantly below typical industry standards for healthy, growing companies in any of its operating sectors.
• The sharp decline in revenue across multiple segments, such as Genefic (51.7% decrease in 3 months) and Dalrada Climate Technology (82.1% decrease in 3 months), indicates underperformance compared to industry growth rates, particularly in the healthcare and technology sectors which often see robust demand.
• The reliance on related party financing and the technical default on EIDL loans suggest a lack of access to conventional financing, which is a red flag when compared to financially stable industry peers.
• The persistent material weaknesses in internal controls are a significant governance concern, contrasting with the robust financial reporting and control environments expected of well-managed public companies.

Management Changes

Corporate Governance

Legal Proceedings

• Dalrada Health (a subsidiary) filed a lawsuit against Vivera Pharmaceuticals, Inc. and its CEO, Paul Edalat, for misappropriation of $2,104,509 in joint venture funds (Pala Diagnostics). Vivera filed cross-complaints against Dalrada Financial Corporation and its subsidiaries/officers. The case was stayed as of March 2023 to allow for a valuation and dissolution of Pala Diagnostics.
• A resolution was concluded in January 2023 in a dispute between Likido Ltd. and MAPtech PACKAGING LIMITED, requiring Likido to pay $429,987 in damages, $42,374 in legal costs, and $19,754 in arbitration fees, plus 8% annual interest.
• Kroger Specialty Pharmacy LLC filed lawsuits/preliminary injunctions against Genefic Specialty Pharmacy and two of its employees (former Kroger employees) in Tennessee and Alabama, based on non-compete clauses. A preliminary injunction was granted against the Tennessee employee in April 2024.

Related Party Transactions

• The company received cash funding or expenses paid on its behalf from related parties totaling $2,913,980 for the nine months ended March 31, 2024, and $9,252,846 for the nine months ended March 31, 2023, primarily through quarterly promissory notes.
• Accounts payable and accrued liabilities to related parties amounted to $254,295 as of March 31, 2024, and $547,949 as of June 30, 2023.
• Revenues from related parties with common ownership totaled $1,639,805 for the nine months ended March 31, 2024, with Bothof Brothers contributing $1,614,458 of this amount.
• On March 29, 2024, $13,318,783 of related party debt principal and interest was converted into 15,951 shares of Series I Convertible Preferred Stock.
• Several notes payable to related entities are in default, but the company has not received any notices of default or demands for payment.

Stakeholder Impact

• Shareholders face significant dilution risk due to ongoing equity sales and conversions of related party debt into preferred and common stock. The substantial net losses, accumulated deficit, and explicit going concern doubt pose a fundamental risk to their investment value.
• Employees and consultants are impacted by stock-based compensation, which is a notable component of remuneration. Legal proceedings involving employees (e.g., Kroger lawsuit) could create uncertainty or affect morale.
• Creditors, particularly those holding related party notes, face increased risk given that several notes are in default, although no demands for payment have been made. The company's going concern status heightens risk for all lenders.
• Customers may experience impacts from the significant decrease in sales activity across multiple business segments, potentially indicating reduced service availability or product offerings, or a decline in customer demand.

Next Steps

• Raise substantial capital through debt or equity financing to fund operations, capital expenditures, working capital, and other cash requirements.
• Accelerate sales and marketing efforts for high-margin products, including Likido heating & cooling units, precision parts, Dalrada Energy Services, DepTec's deposition systems, and COVID-19 testing.
• Double the class size for the Dalrada Career Institute's RN nursing program in 2025.
• Remediate identified material weaknesses in internal control over financial reporting by standardizing reconciliation processes and enhancing financial policies and procedures.
• Finalize the transfer of ownership documentation for EIDL loans with the Small Business Administration to address technical defaults.
• Address and resolve ongoing legal proceedings, including the Vivera lawsuit and the Kroger Specialty Pharmacy lawsuits.

Key Dates

Recommendation

Keywords

Dalrada Financial Corporation, DFCO, SEC filing, 10-Q/A, Quarterly Report, Financial Performance, Net Loss, Revenue Decline, Going Concern, Liquidity, Working Capital, Related Party Transactions, Internal Controls, Legal Proceedings, Healthcare, Climate Technology, Precision Manufacturing, Technology Services, Stock-based Compensation, Preferred Stock, Convertible Debt, Auditor Resignation, Board Resignation, Expert Market